The United Arab Emirates CDMO market was valued at USD 2.98 Billion in 2025 and is expected to grow at a CAGR of 5.40%, reaching USD 5.04 Billion by 2035. The market is driven by robust government support and strategic global alliances across the region. Additionally, the UAE’s geographic location and logistics connectivity offer a competitive export advantage across MENA and Asia. These strengths, combined with opportunities like increased demand for metabolic disease trials and AI-driven CRO models, are expected to accelerate market expansion and international CDMO collaborations.
Base Year
Historical Period
Forecast Period
The UAE is advancing its CDMO sector through sovereign-backed investments such as the Resilience-Mubadala biopharma facility, enhancing regional drug security and innovation.
Collaborations like IROS and Halia Therapeutics highlight the UAE’s rising profile in clinical research, particularly in obesity and metabolic disease trials.
Mubadala’s 2024 acquisition of KELIX bio and GlobalOne pharma assets expands UAE’s domestic manufacturing capacity and positions it as a regional export hub.
Compound Annual Growth Rate
5.4%
Value in USD Billion
2026-2035
*this image is indicative*
The UAE CDMO market supports national healthcare resilience and regional production ambitions. Bolstered by government-supported biotech hubs, strategic geographic positioning, and integrated supply infrastructure, it delivers advanced drug substance and product capabilities, from APIs to sterile injectables, meeting both local needs and international standards while attracting cross-border investment and enhancing pharmaceutical self-sufficiency.
Strengthened Biopharma Ecosystem Through National Acquisitions to Boost Market Growth
Robust public investment and strategic consolidation are key enablers of UAE’s CDMO market. For instance, in March 2024, Mubadala Investment Company secured a takeover of KELIX bio along with four key GlobalOne pharma assets, expanding capabilities in oral solids, sterile injectables, IV solutions, and complex generics. This acquisition boosts local manufacturing breadth, accelerates technology integration, and supports export readiness. As part of UAE Vision initiatives, this strengthens resilience and fuels CDMO growth by embedding advanced production services across the biopharma value chain.
Major market trends include sovereign-backed biomanufacturing projects and global-standard CRO collaborations.
Strategic Biomanufacturing Initiatives Gaining Momentum and Boosting Market Value
UAE is prioritizing biopharma infrastructure due to sovereign wealth funding and localized production mandates. For instance, in April 2024, National Resilience and Mubadala announced a joint venture to build the UAE’s first GMP-compliant biomanufacturing facility in Abu Dhabi. The facility will manufacture advanced biologics, including vaccines and cancer therapies, strengthening domestic supply chains and integrating the UAE into Resilience’s global CDMO network. This reflects rising national interest in health sovereignty and competitive bioproduction.
Clinical Research Expansion through International Partnerships to Meet Rising United Arab Emirates CDMO Market Demand
Spurred by regulatory efficiency and AI-enabled healthcare systems, the UAE is advancing CRO capabilities. For instance, in January 2025, IROS (under M42 Group) partnered with US-based Halia Therapeutics to launch a clinical trial targeting obesity and type 2 diabetes. This partnership exemplifies the UAE’s strategic role in regional clinical research, using local talent and infrastructure to support multinational trials. It enhances competitiveness in the Middle East’s CRO landscape.
Oncological Diseases to Lead the Market by Therapeutic Area
The oncological diseases segment leads the market due to rising cancer incidence and increased investment in precision biologics. It is projected to reach USD 3.77 billion by 2034 at a CAGR of 6.6% during the forecast period. Government-backed screening programs and growing awareness are driving demand for advanced therapeutics and trial services. CDMO players are leveraging this demand through formulation, sterile fill-finish, and packaging services for targeted therapies. Infectious and metabolic disorders are also growing due to public health programs and increased lifestyle-related conditions.
The key features of the market report comprise grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1982 and headquartered in Sharjah, Al Hayat Pharmaceuticals has been instrumental in the UAE’s pharmaceutical supply chain. The company has recently expanded its focus to CDMO activities, providing secondary packaging and quality control services. Al Hayat collaborates with leading global biotech firms to localize medical products in compliance with UAE’s regulatory frameworks, supporting national healthcare sustainability and pharma manufacturing initiatives.
Based in Stockholm, Sweden and founded in 1995, Recipharm is actively expanding its CDMO operations in the Middle East. The firm supplies finished dose manufacturing and formulation support for clients operating in the UAE market. It works through strategic partnerships with regional stakeholders to integrate quality assurance systems and supports biotech transfer capabilities aligned with UAE compliance norms.
Headquartered in Ingelheim, Germany since 1885, Boehringer Ingelheim has been involved in the UAE’s healthcare sector via collaborations and regulatory engagement. The company contributes to biopharmaceutical research and contract manufacturing dialogues in the UAE, especially in areas of respiratory and metabolic disorders, through thought leadership and policy-aligned development forums.
Thermo Fisher, through its Patheon CDMO division, supports UAE clients with access to global-scale development, formulation, and manufacturing solutions. Although headquartered in Massachusetts, USA, the company partners with UAE pharmaceutical firms for custom sterile injectables, clinical trial support, and regulatory consultancy, especially relevant with the country’s growing Phase I–IV trial pipeline.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., NewBridge Pharmaceuticals, Lonza Group, Modern Pharmaceutical Company LLC (MPC), WuXi AppTec, Fareva SA, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share